The US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Adcetris ...

Danish biopharma giant Novo Nordisk (NOV: N) is breaking new ground with its GLP-1 agonist semaglutide, as a small mid-stage ...

Australian radiopharma company Telix Pharmaceuticals (ASX: TLX) has gained approval from the UK Medicines and Healthcare ...

IN8bio has announced encouraging new clinical data from its ongoing Phase I trial of INB-100, an allogeneic gamma-delta T ...

Shares in AnaptysBio, a San Diego-based biotech focused on delivering innovative immunology therapeutics, was trading 19% ...

England’s National Institute for Health and Care Excellence (NICE), and Canada’s Drug Agency (CDA-AMC) have formed the Health Economics Methods Advisory (HEMA) initiative. The goal of HEMA is to ...

Massachusetts, USA-based cell therapy specialist Abcuro today announced the closing of a $200 million Series C financing.

An Expert View from Nick Petschek, EMEA managing director at global change management firm Kotter International.

US pharma major AbbVie has announced a deal with Xilio Therapeutics, more than doubling the latter’s share price.

Royalty Pharma has entered into an agreement with Biogen to provide research and development (R&D) funding for the US biotech ...

Biogen reported fourth-quarter 2024 earnings that surpassed analysts' expectations, driven by strong sales of new product ...

At least 90% of drugs from the list of vital medicines in Russia will be of domestic origin already by the end of 2025, ...